GW's Epidiolex Epilepsy Data Paves Way For Cannabinoids

Safety and efficacy in study published in New England Journal of Medicine bode well for cannabinoid therapy Epidiolex, which is headed to FDA mid-year.

Epidolex

The positive reception of Phase III data for GW Pharmaceuticals PLC's cannabinoid therapy Epidiolex for Dravet syndrome, a severe type of pediatric epilepsy, in the New England Journal of Medicine is an important step for pharmaceutical-grade cannabinoids as a therapeutic option for neurological disorders as well as other diseases.

Derived from the marijuana plant, Epidiolex includes cannabidiol (CBD) but not the psychoactive tetrahydrocannabinol (THC). The drug is one of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category